Program
Ezetimibe
Also written as “ezetimibe”, “ezetimibe (+) simvastatin” and “MK0653, ezetimibe”.
Its studies are mostly in Hypercholesterolemia · Hypertension · Hyperlipidemias · Lipid Metabolism, Inborn Errors · Atherosclerosis, led by 16 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 710 open or running | phase 4since Sep 7, 2005 | Sep 23, 2004 | none ahead |
| Daiichi Sankyo | 61 open or running | phase 4since Sep 9, 2005 | Sep 9, 2005 | Jun 1, 2028phase 3 · NCT07474649 |
| Yuhan | 40 open or running | phase 4since Jul 12, 2017 | Jul 12, 2017 | none ahead |
| IlDong Pharmaceutical | 20 open or running | phase 3since Sep 25, 2014 | Sep 25, 2014 | none ahead |
| JW Pharmaceutical | 21 open or running | phase 4since Feb 18, 2026 | Oct 6, 2020 | none ahead |
| Novartis | 20 open or running | phase 4since Oct 10, 2006 | Sep 12, 2005 | none ahead |
| Celltrion | 10 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | none ahead |
| Daewon Pharmaceutical | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Mar 22, 2012 | Mar 22, 2012 | none ahead |
| Hanlim Pharm. | 10 open or running | phase 3since Dec 2, 2020 | Dec 2, 2020 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 1since Apr 29, 2014 | Apr 29, 2014 | none ahead |
| HK inno.N | 10 open or running | phase 4since Nov 20, 2018 | Nov 20, 2018 | none ahead |
| hyundai-pharm | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| Merck | 10 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| NVP Healthcare | 10 open or running | phase 1since Nov 9, 2014 | Nov 9, 2014 | none ahead |
| Shin Poong Pharmaceutical | 10 open or running | phase 3since Aug 18, 2017 | Aug 18, 2017 | none ahead |
Also a collaborator on its studies: pharma-medica-research-inc, Regeneron Pharmaceuticals, merck-frosst-canada-ltd, linical-korea and medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 40 studies since Mar 31, 2008.
- Nov 20, 2018HK inno.N's first study: phase 4 study in HypertensionNew to HK inno.NHK inno.N · NCT03847506 · 127 enrolled · Korea, Republic of
- Mar 6, 20195 phase 3 studiesOrganon · NCT03884452, NCT03867110, NCT03882996 and 2 more
- Mar 11, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT03872232 · 180 enrolled · Korea, Republic of
- Aug 8, 2019Phase 4 study in Acute Coronary SyndromeYuhan · NCT04056169 · 50 enrolled · Korea, Republic of
- Nov 7, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT04158076 · 131 enrolled · Korea, Republic of
- Oct 6, 2020JW Pharmaceutical's first study: phase 3 study in Primary HypercholesterolemiaNew to JW PharmaceuticalJW Pharmaceutical · NCT04584736 · 283 enrolled · Korea, Republic of
- Dec 2, 2020Hanlim Pharm.'s first study: phase 3 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT04659070 · 156 enrolled · Korea, Republic of
- Jul 24, 2023Daewon Pharmaceutical's first study: phase 3 study in HypercholesterolemiaNew to Daewon PharmaceuticalDaewon Pharmaceutical · NCT05970679 · 252 enrolled · Korea, Republic of
- Oct 15, 2024hyundai-pharm's first study: phase 3 study in HypertensionNew to hyundai-pharmhyundai-pharm · NCT06646354 · 125 planned · Korea, Republic of
- Sep 11, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07182383, NCT07201545
- Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
- Feb 18, 2026Phase 4 study in HypercholesterolemiaJW Pharmaceutical · NCT07442630 · 88 enrolled · South Korea
- Mar 11, 2026Phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649 · 103 planned · Germany, Italy, Spain
- Apr 27, 2026Celltrion's first study: phase 3 study in HypertensionNew to CelltrionCelltrion · NCT07564726 · 163 enrolled · South Korea
Ahead
- Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649
TargetBeta
“Niemann-Pick C1-like protein 1 inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 97 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07564726Hypertension · South Korea | 3 | Completed | Celltrion | Feb 13, 2024 | 163 |
| NCT07474649Coronary Artery Disease · Germany, Italy, Spain | 3 | Not yet recruiting | Daiichi Sankyo | Jun 1, 2028 | 103 |
| NCT07442630Hypercholesterolemia · South Korea | 4 | Active, not recruiting | JW Pharmaceutical | Jan 22, 2026 | 88 |
| NCT07268625Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Feb 24, 2026 | 58 |
| NCT07235189Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Jan 28, 2026 | 58 |
| NCT07201545Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Dec 10, 2025 | 58 |
| NCT07182383Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Nov 24, 2025 | 58 |
| NCT06646354Hypertension · Korea, Republic of | 3 | By invitation | hyundai-pharm | May 19, 2025 | 125 |
| NCT05970679Hypercholesterolemia · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Apr 13, 2023 | 252 |
| NCT04659070Hypertension · Korea, Republic of | 3 | UNKNOWN | Hanlim Pharm. | May 19, 2022 | 156 |
| NCT04584736Primary Hypercholesterolemia · Korea, Republic of | 3 | Completed | JW Pharmaceutical | Jul 16, 2020 | 283 |
| NCT04158076Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Jan 14, 2021 | 131 |
| NCT04056169Acute Coronary Syndrome · Korea, Republic of | 4 | Completed | Yuhan | Jul 23, 2019 | 50 |
| NCT03882996Hypercholesterolemia | 3 | Completed | Organon | Feb 4, 2003 | 432 |
| NCT03882905Primary Hypercholesterolemia | 3 | Completed | Organon | Jul 27, 2001 | 769 |
| NCT03882892Hypercholesterolemia | 3 | Completed | Organon | Aug 8, 2002 | 400 |
| NCT03872232Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Aug 12, 2020 | 180 |
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | Organon | May 24, 2001 | 50 |
| NCT03867110Hypercholesterolemia | 3 | Completed | Organon | Jul 27, 2001 | 628 |
| NCT03847506Hypertension · Korea, Republic of | 4 | Completed | HK inno.N | Dec 2, 2020 | 127 |
| NCT03288038Hypercholesterolemia · Korea, Republic of | 3 | Completed | Shin Poong Pharmaceutical | Nov 19, 2015 | 382 |
| NCT03217409Diabetes Mellitus · Korea, Republic of | 4 | Completed | Yuhan | Apr 3, 2019 | 85 |
| NCT02748057Hypercholesterolemia | 3 | Completed | Organon | Dec 11, 2017 | 135 |
| NCT02749994Hypercholesterolemia · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Feb 2017 | 396 |
| NCT02741245Hypercholesterolemia | 3 | Completed | Organon | Jan 18, 2017 | 321 |
| NCT02550288Hypercholesterolemia | 3 | Completed | Organon | May 30, 2016 | 309 |
| NCT02460159Hypercholesterolemia | 3 | Completed | Organon | Dec 22, 2016 | 135 |
| NCT02289430Healthy | 1 | Completed | NVP Healthcare | Feb 2015 | 59 |
| NCT02251847Hypercholesterolemia · Korea, Republic of | 3 | UNKNOWN | IlDong Pharmaceutical | Jul 2015 | 400 |
| NCT02127320Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Sep 2014 | 24 |
| NCT01611883Hypercholesterolemia | 4 | Completed | Organon | Jan 16, 2014 | 152 |
| NCT01597700Hypercholesterolemia · India | 1 | Completed | GlaxoSmithKline | Jan 30, 2012 | 52 |
| NCT01370603Hypercholesterolemia | 3 | Completed | Organon | May 2012 | 328 |
| NCT01370590Hypercholesterolemia | 3 | Completed | Organon | Apr 2012 | 406 |
| NCT01154036Hypercholesterolemia | 3 | Completed | Organon | Sep 2012 | 1,547 |
| NCT00871351Primary Hypercholesterolemia | 4 | Completed | Organon | May 1, 2010 | 125 |
| NCT00867165Primary Hypercholesterolemia | 3 | Completed | Organon | Apr 13, 2012 | 138 |
| NCT00862251Cardiovascular Diseases | 3 | Completed | Organon | Mar 2011 | 808 |
| NCT00753883Hyperlipidemias | 4 | Completed | Merck | May 2008 | 40 |
| NCT00654628Hypercholesterolemia | 4 | Completed | Organon | Jul 1, 2009 | 173 |
| NCT00654095Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2009 | 146 |
| NCT00653835Hypercholesterolemia | 4 | Completed | Organon | Aug 1, 2004 | 153 |
| NCT00653796Hypercholesterolemia | 4 | Completed | Organon | Aug 1, 2004 | 148 |
| NCT00653523Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2009 | 151 |
| NCT00653276Cholesterol | 1 | Completed | Organon | Jan 2004 | 13 |
| NCT00652847Hypercholesterolemia | 4 | Completed | Organon | May 2007 | 1,140 |
| NCT00652717Cardiovascular Diseases | 4 | Completed | Organon | Feb 15, 2005 | 280 |
| NCT00653913Hypercholesterolemia | 1 | Completed | Organon | Sep 2004 | 18 |
| NCT00652444Hypercholesterolemia | 4 | Completed | Organon | Aug 2004 | 120 |
| NCT00652327Hypercholesterolemia | 4 | Completed | Organon | Jul 2007 | 83 |
| NCT00652301Cholesterol | 3 | Completed | Organon | Apr 2004 | 40 |
| NCT00651963Lipid Metabolism Disorders | 4 | Completed | Organon | Mar 2005 | 80 |
| NCT00651560Hyperlipidemias | 3 | Completed | Organon | Dec 23, 2005 | 167 |
| NCT00651404Hypercholesterolemia | 3 | Completed | Organon | Dec 2004 | 137 |
| NCT00651391Hypercholesterolemia | 3 | Terminated | Organon | Sep 1, 2004 | 28 |
| NCT00651274Atherosclerosis | 4 | Completed | Organon | Aug 1, 2004 | 144 |
| NCT00651144Hypercholesterolemia | 1 | Completed | Organon | May 2003 | 40 |
| NCT00651014Hypercholesterolemia | 4 | Terminated | Organon | Jun 2006 | 82 |
| NCT00650819Hypercholesterolemia | 3 | Completed | Organon | Feb 1, 2005 | 240 |
| NCT00650689Hypercholesterolemia | 3 | Completed | Organon | Dec 2004 | 122 |
How it is read
Names in the registry
- “Ezetimibe”, 31 entries
- “ezetimibe”, 11 entries
- “ezetimibe (+) simvastatin”, 10 entries
- “MK0653, ezetimibe”, 7 entries
- “CKD-828, D097, D337”, 6 entries
Codes read as this program: MK0653.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 73 studies
- Hypertension, 9 studies
- Hyperlipidemias, 7 studies
- Lipid Metabolism, Inborn Errors, 3 studies
- Atherosclerosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.